NCT04757974View on ClinicalTrials.gov

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions

HIV Infections

Interventions

DRUG

Fostemsavir 600 mg

Fostemsavir tablets will be administered via oral route.

DRUG

Fostemsavir 200 mg

Fostemsavir tablets will be administered via oral route.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare

All Listed Sponsors

lead

ViiV Healthcare

INDUSTRY